Patent 12168036

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2021-09-08 · reel 057429/0819 · ASSIGNMENT OF ASSIGNORS INTEREST

    WADHWA, SAURABH; GRAHAM, KENNETH S.REGENERON PHARMACEUTICALS, INC.

    Correspondent: · BAKER BOTTS

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Kenneth S. Graham: Employed by Regeneron Pharmaceuticals, Inc. at the time of filing.
  • Saurabh Wadhwa: Employed by Regeneron Pharmaceuticals, Inc. at the time of filing.

No unusual patterns, such as inventors departing the original assignee shortly after filing, are determinable from the provided information.

Original assignee

The original assignee named on the issued patent is Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines. They ship products embodying the claims, specifically EYLEA® and EYLEA HD® (aflibercept), which are used for treating angiogenic eye disorders. Regeneron Pharmaceuticals, Inc. is currently an operating company.

Assignment timeline

  • 2021-09-08 (executed) / recorded 2021-09-08 — Reel 057429/0819
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: WADHWA, SAURABH; GRAHAM, KENNETH S.
    • Assignee: REGENERON PHARMACEUTICALS, INC.
    • Correspondent: BAKER BOTTS L.L.P. 2001 ROSS AVENUE SUITE 900 DALLAS, TX 75201
    • Context: Standard initial assignment from inventors to the employing entity.

Timeline diagram

timeline
    title Ownership of US 12168036
    2021 : Filed by Regeneron
         : Inventors assigned to Regeneron
    2024 : Issued
    2025 : PGR filed Alvotech
    2026 : PGR filed Biocon

NPE / troll-pattern signals

  1. Shell-entity transfer — Not present. The only recorded assignment is from the inventors to Regeneron Pharmaceuticals, Inc., which is an operating company that develops and sells products. [cite: USPTO Assignment Record Reel 057429/0819]
  2. Known asserter in the chain — Not present. Regeneron Pharmaceuticals, Inc. is a known operating company, not a recognized patent assertion entity (NPE). [cite: USPTO Assignment Record Reel 057429/0819]
  3. Repeat correspondent across the chain — Unclear. Baker Botts L.L.P. is listed as the correspondent for the single recorded assignment [cite: USPTO Assignment Record Reel 057429/0819]. However, with only one assignment on record for this specific patent, it is not possible to determine if this correspondent recurs across the chain or on other known NPE assertions without a broader search, which is outside the scope of this particular analysis.
  4. Cascading transfers — Not present. There is only one recorded assignment for this patent. [cite: USPTO Assignment Record Reel 057429/0819]
  5. Pre-litigation transfer — Not present. The assignment from the inventors to Regeneron occurred on 2021-09-08, well before the patent was issued on 2024-12-17, and before the initiation of any known PGR proceedings (PGR2025-00085 filed in 2025, PGR2026-00039 filed in 2026). [cite: USPTO Assignment Record Reel 057429/0819]
  6. Bankruptcy fire-sale — Not present. Regeneron Pharmaceuticals, Inc. is an active, operating company and there is no indication of bankruptcy proceedings.
  7. Privateering — Not present. The patent is held by the operating company, Regeneron.
  8. Defensive aggregator (anti-NPE) — Not present. The patent is currently assigned to Regeneron Pharmaceuticals, Inc. and is not shown to be held by a defensive aggregator.

Verdict

Insufficient data

The only recorded assignment for U.S. Patent 12,168,036 is the initial transfer of inventor rights to Regeneron Pharmaceuticals, Inc., recorded on 2021-09-08 (Reel 057429/0819). This is a standard practice and does not provide any signals of NPE activity or transfer patterns. Without further recorded assignments, it is not possible to make a determination regarding NPE status.

USPTO Assignment Center Search for US12168036

Generated 5/29/2026, 9:06:02 PM